MAP2K7 and chronic myelogenous leukemia, BCR-ABL1 positive: In BCR-ABL independent imatinib resistant cells, the increased expression of the protein kinase C (PKC) family member PKCη sustains the RAF/MEK/ERK signaling, leading to CML cell proliferation and inhibition of apoptosis (24).